{"id":34678,"date":"2026-09-30T12:46:08","date_gmt":"2026-09-30T10:46:08","guid":{"rendered":"https:\/\/www.fundacionbankinter.org\/noticias\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/"},"modified":"2026-11-16T13:02:26","modified_gmt":"2026-11-16T12:02:26","slug":"longevity-medicine-what-the-science-really-says-about-living-longer-and-better","status":"publish","type":"noticias","link":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/","title":{"rendered":"Longevity Medicine: What the Science Really Says About Living Longer and Better"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Longevity medicine is experiencing a paradox. We have never known so much about the biological mechanisms of aging. At the same time, the market is advancing much faster than clinical evidence.<\/p>\n\n<p class=\"wp-block-paragraph\">Biological clocks, NAD+ supplements, rapamycin, senolytics, cell reprogramming or regenerative therapies are part of an increasingly visible sector. Some of these lines are supported by decades of research. Others are still in animal models or in very early human trials. Separating them matters.<\/p>\n\n<p class=\"wp-block-paragraph\">The relevant scientific question is no longer simply about how long we can extend life. The goal is to extend <strong>healthspan<\/strong>, the years lived with good health and functional capacity. And there is a solid scientific field, <strong>geroscience<\/strong>, which tries to understand the extent to which intervening on the biological processes of aging can delay various diseases associated with age.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>What Longevity Medicine Really Is<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\"><em>Longevity medicine (or healthy longevity medicine<\/em>) is still an <strong>emerging clinical field<\/strong>. It seeks to transfer advances in geroscience to prevention, diagnosis and interventions aimed at maintaining health for more years.<\/p>\n\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38512582\/\">review published in <em>GeroScience<\/em><\/a> describes this discipline as the integration of geroscience and other medical areas into clinical practice, with multidisciplinary teams, evaluation of risk factors, and monitoring of age-associated functional changes.<\/p>\n\n<p class=\"wp-block-paragraph\">Its best-known biological basis is the <strong><a href=\"https:\/\/doi.org\/10.1016\/j.cell.2022.11.001\">hallmarks of aging<\/a><\/strong>. Carlos L\u00f3pez-Ot\u00edn, Mar\u00eda Blasco, Linda Partridge, Manuel Serrano and Guido Kroemer proposed nine in 2013 and expanded the framework to twelve in 2023.<\/p>\n\n<p class=\"wp-block-paragraph\">These include genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, chronic inflammation or alteration of communication between cells.<\/p>\n\n<p class=\"wp-block-paragraph\">The aim of the research is to understand these processes and discover which ones can be safely modified in humans.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Longevity, ageing and healthy life expectancy<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">It is worth distinguishing concepts. <strong>Ageing<\/strong> describes the biological and functional changes that appear over time. <strong>Longevity<\/strong> indicates how long a person lives. <strong>Life expectancy<\/strong> is a statistical measure of the survival of a population. And <em>healthspan<\/em> tries to measure how long we live in good health.<\/p>\n\n<p class=\"wp-block-paragraph\">The Bankinter Innovation Foundation has already addressed these differences in <a href=\"https:\/\/www.fundacionbankinter.org\/en\/news\/do-you-know-how-to-distinguish-between-longevity-and-aging\/\">Do you know how to distinguish between longevity and ageing?<\/a>.<\/p>\n\n<p class=\"wp-block-paragraph\">Geroscience introduces an additional idea. Ageing is the main risk factor for many chronic diseases, from cardiovascular diseases to cancer, diabetes or neurodegenerative diseases. The <a href=\"https:\/\/www.nia.nih.gov\/gsig\">National Institute on Aging in the United States<\/a> is investigating precisely whether acting on shared processes of aging can simultaneously delay several of these pathologies.<\/p>\n\n<p class=\"wp-block-paragraph\">This hypothesis is very attractive. There is still much to be demonstrated in humans.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>What we know and what we still don&#8217;t know<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">Here is the main difference between science and marketing.<\/p>\n\n<p class=\"wp-block-paragraph\">The biological mechanisms of aging have abundant experimental evidence. Translating them into treatments that prolong human life is much more difficult.<\/p>\n\n<p class=\"wp-block-paragraph\">So far, <strong>no pharmacological intervention specifically aimed at aging has been shown in clinical trials to prolong human life<\/strong>. A <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40591010\/\">2025 review of longevity interventions<\/a> concludes that the gap between public expectations and clinical evidence remains considerable.<\/p>\n\n<p class=\"wp-block-paragraph\">That doesn&#8217;t mean the research has failed. It means we need to distinguish between three levels of evidence: results in cells, results in animals, and demonstrated effects in people. Going from one to the next can take years.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Biological age: a useful idea with important limits<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Chronological age indicates how many years have passed since birth. The so-called <strong>biological age<\/strong> tries to estimate how an organism is doing using different indicators.<\/p>\n\n<p class=\"wp-block-paragraph\">One of the best-known methods is epigenetic clocks. They analyse DNA methylation patterns associated with ageing and produce an estimate of epigenetic age.<\/p>\n\n<p class=\"wp-block-paragraph\">These tools are very valuable in research. The problem arises when a figure generated by a clock is presented as if it measured exactly how much the entire organism has aged.<\/p>\n\n<p class=\"wp-block-paragraph\">The reality is more complex: a <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678247\/\">systematic review published in 2026<\/a> analysed 81 clocks built from clinical indicators. It found significant validation problems and risk of bias in many of them. Another review warns that ageing occurs differently depending on tissue and that no single indicator fully represents a person&#8217;s &#8216;biological age&#8217;.<\/p>\n\n<p class=\"wp-block-paragraph\">For this reason, these watches can be useful for investigating trends or responses to an intervention, but <strong>a commercial result of &#8220;you are 42 years old&#8221; does not equate to a medical diagnosis<\/strong>.<\/p>\n\n<p class=\"wp-block-paragraph\">The Foundation has recently delved into this topic by explaining <a href=\"https:\/\/www.fundacionbankinter.org\/en\/news\/what-is-the-epigenome-and-how-is-it-altered-by-lifestyle-habits\/\">what the epigenome is and how it is altered by lifestyle habits<\/a>.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Rapamycin: Lots of Animal Evidence, First Responses in Humans<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.revespcardiol.org\/es-la-rapamicina-del-laboratorio-al-tratami-articulo-13049514\">Rapamycin<\/a><\/strong> is at the heart of longevity research. It inhibits mTOR, a cellular pathway related to growth, metabolism and nutrient response, and has been able to prolong life in different animal species.<\/p>\n\n<p class=\"wp-block-paragraph\">The question is what happens in humans. The <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40188830\/\"><strong>PEARL<\/strong> trial<\/a>, published in 2025, evaluated intermittent low doses of rapamycin versus placebo in healthy adults for 48 weeks. It was a randomized, double-blind trial.<\/p>\n\n<p class=\"wp-block-paragraph\">Adverse effects were similar between groups, providing information on safety. However, <strong>the primary endpoint, visceral fat reduction, showed no significant differences<\/strong>. Some improvements appeared in secondary variables and in certain subgroups, but the authors themselves point out that more studies are needed to establish efficacy.<\/p>\n\n<p class=\"wp-block-paragraph\">The research continues. In March 2026, <strong><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06658093\">RESTOR<\/a><\/strong>, a study supported by the <a href=\"https:\/\/www.nih.gov\/\">NIH,<\/a> the main public biomedical research agency in the United States, began, which analyzes rapamycin and <a href=\"https:\/\/cima.aemps.es\/cima\/dochtml\/p\/83503\/P_83503.html\">everolimus<\/a> in older people to determine doses and guidelines capable of safely inhibiting mTOR.<\/p>\n\n<p class=\"wp-block-paragraph\">It&#8217;s a good example of where the field really stands: far from being able to recommend rapamycin as a longevity treatment, but advanced enough to warrant controlled clinical trials.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>NAD+: A Promise Still Seeking Clear Clinical Benefits<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Another of the big stars in the longevity market is <strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37364580\/\">NAD+<\/a><\/strong>, a coenzyme essential for energy metabolism, DNA repair and different cell signalling processes. Its levels tend to decrease with age, which has driven research into strategies to increase them.<\/p>\n\n<p class=\"wp-block-paragraph\">Compounds such as <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37619764\/\">NMN (nicotinamide mononucleotide)<\/a> and <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37630330\/\">nicotinamide riboside or NR<\/a> are used as precursors to NAD+ and have sparked a great deal of interest in aging research. A huge market for supplements has emerged from there as well.<\/p>\n\n<p class=\"wp-block-paragraph\">The evidence on its clinical benefits is much less conclusive. A <a href=\"https:\/\/www.nature.com\/articles\/s42255-025-01387-7\">review published in <em>Nature Metabolism<\/em> in 2025<\/a> concluded that human trials show <strong>limited efficacy<\/strong> so far, while questions remain open about tissue differences, dosage, long-term safety, and which groups might benefit.<\/p>\n\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275690\/\">systematic review and meta-analysis on NMN and NR<\/a> also found no clear improvements in strength, muscle mass, or physical function in older adults.<\/p>\n\n<p class=\"wp-block-paragraph\">The conclusion is the same again: interesting biological mechanism, promising preclinical results, and human evidence still insufficient for many of the commercial promises.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Senolytics: eliminate cells that stop working properly<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Senescent cells have stopped dividing, but they remain metabolically active and can release inflammatory molecules that affect tissues.<\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/scielo.isciii.es\/scielo.php?pid=S1889-836X2023000300004&amp;script=sci_arttext\"><strong>Senolytics<\/strong><\/a> try to selectively eliminate senescent cells.<\/p>\n\n<p class=\"wp-block-paragraph\">The combination of <a href=\"https:\/\/cima.aemps.es\/cima\/dochtml\/p\/84090\/Prospecto.html\"><strong>dasatinib<\/strong><\/a> and <a href=\"https:\/\/scielo.isciii.es\/scielo.php?pid=S1889-836X2023000300004&amp;script=sci_arttext\"><strong>quercetin<\/strong><\/a> is one of the most studied. Dasatinib is a tyrosine kinase inhibitor used in certain types of leukemia, while quercetin is a flavonoid naturally present in fruits and vegetables. A <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31542391\/\">small pilot trial published in 2019<\/a> in people with diabetic kidney disease showed a reduction in several markers of senescence after treatment.<\/p>\n\n<p class=\"wp-block-paragraph\">But subsequent studies remind us of the caution needed. A <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38956196\/\">Mayo Clinic phase 2 trial published in <em>Nature Medicine<\/em> in 2024<\/a> evaluated this combination in 60 postmenopausal women. <strong>The primary endpoint related to bone resorption did not improve significantly in the group as a whole<\/strong>. Interesting signs did appear in exploratory analyses of women with a higher senescent cell load.<\/p>\n\n<p class=\"wp-block-paragraph\">This is promising science. It is not yet a proven anti-aging therapy.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Cellular reprogramming: the most ambitious frontier<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">An even more experimental line tries to rejuvenate cells through <strong>partial reprogramming<\/strong>.<\/p>\n\n<p class=\"wp-block-paragraph\">The starting point is the Yamanaka factors, capable of <a href=\"https:\/\/www.fundacionbankinter.org\/en\/news\/what-induced-pluripotent-stem-cells-ips-are-and-why-they-are-transforming-medicine\/\">returning adult cells to a pluripotent state<\/a>. Partial reprogramming seeks something more complex: to recover characteristics associated with young cells without causing them to lose their identity.<\/p>\n\n<p class=\"wp-block-paragraph\">Preclinical results have aroused enormous interest. Also huge investments. <strong><a href=\"https:\/\/www.altoslabs.com\/\">Altos Labs<\/a><\/strong> was born in 2022 with 3,000 million dollars committed to research cell rejuvenation. As of September 2026, the company itself continues to describe its rejuvenation results as <strong><a href=\"https:\/\/www.altoslabs.com\/science\">preclinical<\/a><\/strong> and is working on their translation into future drugs. The difference between potential and available intervention is still enormous.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>What does have much stronger evidence today<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">While the sector is looking for drugs capable of modifying the mechanisms of aging, there are less spectacular interventions with much greater support.<\/p>\n\n<p class=\"wp-block-paragraph\">Regular physical activity, healthy eating, adequate sleep and avoiding smoking are consistently associated with lower mortality and more years of healthy life.<\/p>\n\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38684374\/\">study published in 2024<\/a> with more than 350,000 participants from the <a href=\"https:\/\/www.ukbiobank.ac.uk\/\">UK Biobank<\/a> found that healthy lifestyles substantially reduced the risk associated with a genetic predisposition to a shorter life.<\/p>\n\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41768982\/\">more recent analysis by the UK Biobank<\/a> has also reinforced the joint relationship between sleep, exercise, diet and <em>healthspan<\/em>.<\/p>\n\n<p class=\"wp-block-paragraph\">These are less striking interventions than a cocktail of supplements or a cell therapy, but their evidence is much greater.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Longevity has also become an opportunity for innovation<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Scientific interest has created a new business sector in parallel.<\/p>\n\n<p class=\"wp-block-paragraph\">Biomarkers, diagnostics, drug discovery, artificial intelligence applied to biology, regenerative medicine, cell therapies and reprogramming platforms are attracting talent and capital.<\/p>\n\n<p class=\"wp-block-paragraph\">The <a href=\"https:\/\/www.prnewswire.com\/news-releases\/altos-labs-launches-with-the-goal-to-transform-medicine-through-cellular-rejuvenation-programming-301463541.html\">launch of Altos Labs with <strong>3,000 million dollars in initial funding<\/strong><\/a> showed the extent to which investors are willing to make long-term bets on this field.<\/p>\n\n<p class=\"wp-block-paragraph\">Here too, it is worth distinguishing two markets. On the one hand, there is biotechnology, which tries to discover new interventions through scientific research and clinical trials. On the other, a consumer market that markets tests, supplements and treatments whose evidence can be very uneven. Confusing the two fuels hype.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>How to distinguish marketing science from longevity<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">There are some particularly useful signs.<\/p>\n\n<p class=\"wp-block-paragraph\">Be wary when an intervention promises to &#8220;reverse age&#8221; without explaining what biomarker it is measuring; when a result in mice is presented as a demonstrated benefit in humans; when small studies are cited without mentioning their limitations; or when an experimental compound is sold as if its efficacy is already established.<\/p>\n\n<p class=\"wp-block-paragraph\">It is also important to review conflicts of interest. In August 2026, an editorial in <em>Nature Medicine<\/em> summed up the problem clearly: <a href=\"https:\/\/www.nature.com\/articles\/s41591-026-04611-3\">anti-aging interventions need <strong>less hype and more clinical evidence<\/strong><\/a>, and specifically pointed out the gap that still exists between the commercial popularity of products like NAD+ and the benefits demonstrated in human trials.<\/p>\n\n<p class=\"wp-block-paragraph\">Scientific longevity deserves interest precisely because there are still many open questions.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Living longer matters. Living better, even more<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Geroscience has changed our understanding of aging. Today we know about cellular mechanisms that a few decades ago could hardly be studied and we have tools capable of measuring them, modifying them in animal models and starting to test them in humans.<\/p>\n\n<p class=\"wp-block-paragraph\">But the distance between understanding aging and controlling it clinically is still large.<\/p>\n\n<p class=\"wp-block-paragraph\">Rapamycin, NAD+, senolytics and cell reprogramming represent relevant lines of research. None of them today allows us to say that we know how to pharmacologically delay human ageing and prolong life.<\/p>\n\n<p class=\"wp-block-paragraph\">The real innovation lies precisely in walking this path.<\/p>\n\n<p class=\"wp-block-paragraph\">At the Bankinter Innovation Foundation, we have been analysing longevity for years from its scientific, economic and social dimensions. Our <a href=\"https:\/\/www.fundacionbankinter.org\/en\/ftf-informes\/longevity\/\">Future Trends Forum report on longevity<\/a> already raised one of the challenges that is still fully valid: ensuring that the increase in years of life is accompanied by more years of health.<\/p>\n\n<p class=\"wp-block-paragraph\">That continues to be the objective worth pursuing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Longevity medicine seeks to extend the years of healthy life by acting on the mechanisms of aging. We analyze which therapies have scientific backing, which are still in the experimental phase, and where the evidence ends and the hype begins.<\/p>\n","protected":false},"featured_media":34349,"template":"","meta":{"_acf_changed":false,"_oaas_summary":"Longevity medicine sits at a paradox: biological understanding of aging has leapt forward, yet the commercial market is advancing faster than clinical proof. Geroscience frames aging as a modifiable set of processes\u2014the \u201challmarks\u201d expanded from nine to twelve\u2014that underlie many chronic diseases. Longevity medicine aims to translate these insights into prevention, diagnostics and treatments to extend healthspan (years lived in good health), not just lifespan. However, promising avenues such as biological clocks, NAD+ boosters, rapamycin, senolytics and cell reprogramming range from well-supported animal data to early or inconclusive human trials, so distinguishing preclinical promise from proven therapies is essential.\n\nNo drug has yet been definitively shown in clinical trials to slow human aging. Tools like epigenetic clocks are valuable research measures but have limits and validation issues for individual diagnosis. Rapamycin shows safety signals and mixed efficacy in early trials; NAD+ precursors and senolytics have intriguing biology but limited demonstrated benefit in people; cell reprogramming remains preclinical despite major investments. By contrast, lifestyle measures\u2014exercise, healthy diet, sleep and no smoking\u2014have robust evidence for extending healthspan. The field\u2019s progress demands rigorous trials, clearer biomarkers, and caution against hype so that longer lives also become healthier lives.","_oaas_audio_url":"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2026\/11\/summary-34678-1794830551.mp3"},"categories":[204,193],"class_list":["post-34678","noticias","type-noticias","status-publish","has-post-thumbnail","hentry","category-science-and-technology","category-social-transformation"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Longevity Medicine: What the Science Really Says<\/title>\n<meta name=\"description\" content=\"What is longevity medicine, what is supported by scientific evidence and what is just hype: biomarkers, therapies and trends in the sector.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longevity Medicine: What the Science Really Says\" \/>\n<meta property=\"og:description\" content=\"What is longevity medicine, what is supported by scientific evidence and what is just hype: biomarkers, therapies and trends in the sector.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/\" \/>\n<meta property=\"og:site_name\" content=\"Fundaci\u00f3n Innovaci\u00f3n Bankinter\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FundacionBankinter\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T12:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2026\/09\/AdobeStock_1971577869-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@FundacionBKT\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/\",\"url\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/\",\"name\":\"Longevity Medicine: What the Science Really Says\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/AdobeStock_1971577869-scaled.jpeg\",\"datePublished\":\"2026-09-30T10:46:08+00:00\",\"dateModified\":\"2026-11-16T12:02:26+00:00\",\"description\":\"What is longevity medicine, what is supported by scientific evidence and what is just hype: biomarkers, therapies and trends in the sector.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/AdobeStock_1971577869-scaled.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/AdobeStock_1971577869-scaled.jpeg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longevity Medicine: What the Science Really Says About Living Longer and Better\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/\",\"name\":\"Fundaci\u00f3nInnovaci\u00f3nBankinter\",\"description\":\"Una organizaci\u00f3n con la misi\u00f3n de promover la creaci\u00f3n de riqueza en nuestro pa\u00eds a trav\u00e9s de la innovaci\u00f3n y el emprendimiento.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/#organization\",\"name\":\"Fundaci\u00f3n Innovaci\u00f3n Bankinter\",\"url\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Logo-Fundacion.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Logo-Fundacion.jpg\",\"width\":2225,\"height\":1454,\"caption\":\"Fundaci\u00f3n Innovaci\u00f3n Bankinter\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fundacionbankinter.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/FundacionBankinter\",\"https:\\\/\\\/x.com\\\/FundacionBKT\",\"https:\\\/\\\/www.instagram.com\\\/fibankinter\\\/?hl=es\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/fundacion-innovaci\u00f3n-bankinter\\\/?viewAsMember=true\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCIBC-qbnAX_-DAH9-_vvLuw\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longevity Medicine: What the Science Really Says","description":"What is longevity medicine, what is supported by scientific evidence and what is just hype: biomarkers, therapies and trends in the sector.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/","og_locale":"en_US","og_type":"article","og_title":"Longevity Medicine: What the Science Really Says","og_description":"What is longevity medicine, what is supported by scientific evidence and what is just hype: biomarkers, therapies and trends in the sector.","og_url":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/","og_site_name":"Fundaci\u00f3n Innovaci\u00f3n Bankinter","article_publisher":"https:\/\/www.facebook.com\/FundacionBankinter","article_modified_time":"2026-11-16T12:02:26+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2026\/09\/AdobeStock_1971577869-scaled.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@FundacionBKT","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/","url":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/","name":"Longevity Medicine: What the Science Really Says","isPartOf":{"@id":"https:\/\/www.fundacionbankinter.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/#primaryimage"},"image":{"@id":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2026\/09\/AdobeStock_1971577869-scaled.jpeg","datePublished":"2026-09-30T10:46:08+00:00","dateModified":"2026-11-16T12:02:26+00:00","description":"What is longevity medicine, what is supported by scientific evidence and what is just hype: biomarkers, therapies and trends in the sector.","breadcrumb":{"@id":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/#primaryimage","url":"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2026\/09\/AdobeStock_1971577869-scaled.jpeg","contentUrl":"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2026\/09\/AdobeStock_1971577869-scaled.jpeg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.fundacionbankinter.org\/en\/news\/longevity-medicine-what-the-science-really-says-about-living-longer-and-better\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/www.fundacionbankinter.org\/en\/news\/"},{"@type":"ListItem","position":2,"name":"Longevity Medicine: What the Science Really Says About Living Longer and Better"}]},{"@type":"WebSite","@id":"https:\/\/www.fundacionbankinter.org\/en\/#website","url":"https:\/\/www.fundacionbankinter.org\/en\/","name":"Fundaci\u00f3nInnovaci\u00f3nBankinter","description":"Una organizaci\u00f3n con la misi\u00f3n de promover la creaci\u00f3n de riqueza en nuestro pa\u00eds a trav\u00e9s de la innovaci\u00f3n y el emprendimiento.","publisher":{"@id":"https:\/\/www.fundacionbankinter.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fundacionbankinter.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fundacionbankinter.org\/en\/#organization","name":"Fundaci\u00f3n Innovaci\u00f3n Bankinter","url":"https:\/\/www.fundacionbankinter.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fundacionbankinter.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2021\/09\/Logo-Fundacion.jpg","contentUrl":"https:\/\/www.fundacionbankinter.org\/wp-content\/uploads\/2021\/09\/Logo-Fundacion.jpg","width":2225,"height":1454,"caption":"Fundaci\u00f3n Innovaci\u00f3n Bankinter"},"image":{"@id":"https:\/\/www.fundacionbankinter.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/FundacionBankinter","https:\/\/x.com\/FundacionBKT","https:\/\/www.instagram.com\/fibankinter\/?hl=es","https:\/\/www.linkedin.com\/company\/fundacion-innovaci\u00f3n-bankinter\/?viewAsMember=true","https:\/\/www.youtube.com\/channel\/UCIBC-qbnAX_-DAH9-_vvLuw"]}]}},"_links":{"self":[{"href":"https:\/\/www.fundacionbankinter.org\/en\/wp-json\/wp\/v2\/noticias\/34678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fundacionbankinter.org\/en\/wp-json\/wp\/v2\/noticias"}],"about":[{"href":"https:\/\/www.fundacionbankinter.org\/en\/wp-json\/wp\/v2\/types\/noticias"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fundacionbankinter.org\/en\/wp-json\/wp\/v2\/media\/34349"}],"wp:attachment":[{"href":"https:\/\/www.fundacionbankinter.org\/en\/wp-json\/wp\/v2\/media?parent=34678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fundacionbankinter.org\/en\/wp-json\/wp\/v2\/categories?post=34678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}